Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 janv. 2022 16h05 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
03 janv. 2022 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
15 déc. 2021 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS Phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving hemoglobin...
13 déc. 2021 11h45 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Improvements demonstrated in treatment-naïve patients and patients with baseline hemoglobin levels greater than or equal to 10.0 g/dLData were presented at the American Society of Hematology (ASH)...
29 nov. 2021 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
18 nov. 2021 16h01 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its...
16 nov. 2021 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its...
15 nov. 2021 16h01 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an...
12 nov. 2021 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that it received formal, written feedback from the U.S. Food and Drug Administration...
10 nov. 2021 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

Pegcetacoplan, an investigational, targeted C3 therapy, has the potential to become the first treatment for GA, a leading cause of blindness worldwide WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE)...

Page précédente